Lynparza™ (olaparib)

LYNPARZA® est indiqué dans 4 indications thérapeutiques. 

Lynpara (olaparib) est le premier inhibiteur de PARP (Poly-ADP-Ribose-Polymérase), qui permet aux femmes atteintes d'un cancer de l’ovaire récidivant sensible au platine avec une mutation BRCA (BReast CAncer) de prolonger la survie sans progression1-3 

Cancer de la prostate

Ressources et supports

Études cliniques

PROfound

Lien vers la publication

Le professeur Sautois et le docteur Van Damme discutent des résultats de l'essai PROfound et de ce que le remboursement signifie pour vos patients

MoA et contrôle génétique

Infographie détaillée sur les contrôles génétiques

Educational videos

Prof. Dr. Sautois on PROfound trial: 
clinical results

Dr. De Putter on germline genetic testing in prostate cancer

Prof. Dr. Pauwels on the failure rate for tissue BRCA testing in clinical practice

Prof. Dr. Pauwels on what we learned
from the PROfound trial

Dr. De Putter on why we should do a tissue test after a negative germline test

Pour patients

Journal pour les patients traités par Lynparza

Événements

Aucun événement pour le moment.

Références

  1. LYNPARZA® 100 mg and 150 mg comprimés pelliculés, Résumé des caractéristiques du produit, version la plus récente
  2. https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/nl/Public/ProductSearch (accès 25/10/2021) 
  3. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015; 60(4):547–560. 
  4. Lord CJ and Ashworth A. PARP inhibitors: The first synthetic lethal targeted therapy. Science. 2017;355(6330):1152–1158. 
  5. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer . N Engl J Med. 2020;382(22):2091–2102. 
  6. de Bono J et al. Poster 847PD. Central, prospective detection of homologous recombination repair gene alterations in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer screened for the PROfound study. Presented at: ESMO Annual Meeting; 27 September-1 October, 2019; Barcelona, Spain. 
  7. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. Supplementary appendix. 
  8. 8. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. Protocol. 
  9. de Bono J et al. Central, prospective detection of homologous recombination repair gene alterations in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer screened for the PROfound study. Poster 847PD. Presented at ESMO An­nual Meeting, 27 September–1 October 2019, Barcelona, Spain. 
  10. Hussain M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020. doi: 10.1056/NEJ­Moa2022485. 
  11. Parker C et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134. 
  12. Cheng HH et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17(5):515– 521. 
  13. Abida W et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Onco. 2017. doi: 10.1200/PO.17.00029 
Retour au sommet